低PSA分泌型转移性去势抵抗性前列腺癌的临床与基因组特征
本研究前瞻性纳入183例转移性去势抵抗性前列腺癌(mCRPC)患者,以血清PSA<5 ng/mL且>5处转移灶定义低PSA分泌型(占8%)。该亚型活检组织t-SCNC和RB1缺失比例更高、AR转录签名评分更低,RB1和/或TP53基因组缺失更常见(80% vs 41%),总生存更短(中位26.7 vs 46.0个月)。
要点
- PSA<5 ng/mL且转移灶>5处可识别低PSA分泌型mCRPC(占8%)。
- 低PSA分泌型富集t-SCNC、RB1缺失及RB1/TP53基因组丢失。
- 低PSA分泌型总生存更短,中位26.7 vs 46.0个月。
核心结论
- 低PSA分泌与转移负荷不匹配可作为识别去分化mCRPC的临床选择工具。
- 该亚型分子特征与t-SCNC一致,需前瞻性验证。
研究设计与样本
- 前瞻性纳入183例无小细胞组织学的mCRPC患者行转移灶活检及分子特征分析。
- 低PSA分泌定义为血清PSA<2、5或10 ng/mL加>5处转移灶且影像学进展。
- 以事后分析比较低PSA分泌型与正常分泌型的临床和分子特征。
主要发现
- 183例中15例(8%)按最佳PSA切点5 ng/mL识别为低PSA分泌型。
- 低PSA分泌型活检t-SCNC和RB1缺失更高、AR转录签名评分更低。
- RB1和/或TP53基因组缺失在低PSA分泌型更常见(80% vs 41%)。
- 低PSA分泌型总生存更短(中位26.7 vs 46.0个月,HR=2.465,95%CI 0.982-6.183)。
- 活检后AR靶向治疗的中位PFS为6.2个月,化疗为4.1个月。
关键数值与推荐
- 低PSA分泌定义:血清PSA<2、5或10 ng/mL加>5处转移灶且影像学进展。
- 最佳PSA切点为5 ng/mL。
- RB1和/或TP53基因组缺失:低PSA分泌型80% vs 正常分泌型41%。
- 总生存:中位26.7 vs 46.0个月,HR=2.465(95%CI 0.982-6.183)。
- 活检后治疗中位PFS:AR靶向治疗6.2个月 vs 化疗4.1个月。
临床怎么用
- 对转移负荷大而PSA低的mCRPC患者考虑转移灶活检行分子分型。
- 识别低PSA分泌型有助于筛选去分化/t-SCNC样肿瘤。
局限性
- 低PSA分泌型样本量小(15例)。
- 低PSA分泌定义为事后分析确定。
- 总生存HR的95%CI跨1。
- 需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic disease burden out of proportion to serum PSA has been used as a marker of aggressive phenotype prostate cancer but is not well defined as a distinct subgroup. We sought to prospectively characterize the molecular features and clinical outcomes of Low PSA Secretors. METHODS: Eligible metastatic castration resistant prostate cancer (mCRPC) patients without prior small cell histology underwent metastatic tumor biopsy with molecular characterization. Low PSA secretion was defined as serum PSA < 2, 5, or 10 ng/mL plus >5 metastases with radiographic progression at study entry. Clinical and molecular features were compared between low PSA vs. normal secretors in a post-hoc fashion. RESULTS: 183 patients were enrolled, including 15 (8%) identified as Low PSA Secretors using optimal PSA cut point of 5 ng/mL. Biopsies from Low PSA Secretors demonstrated higher t-SCNC and RB1 loss and lower AR transcriptional signature scores compared with normal secretors. Genomic loss of RB1 and/or TP53 was more common in Low PSA Secretors (80% vs. 41%). Overall survival (OS) was shorter in Low PSA Secretors (median OS = 26.7 vs. 46.0 months, hazard ratio = 2.465 (95% CI: 0.982-6.183). Progression-free survival (PFS) on post-biopsy treatment with AR-targeted therapy was shorter than with chemotherapy (median PFS 6.2 vs. 4.1 months). CONCLUSIONS: Low PSA secretion in relation to metastatic tumor burden may be a readily available clinical selection tool for de-differentiated mCRPC with molecular features consistent with t-SCNC. Prospective validation is warranted.
引用
- Aggarwal R, Romero GR, Friedl V, et al. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32286548. doi:10.1038/s41391-020-0228-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。